Inflammatory bowel disease is not normally associated with an increased risk of infections. However, immune modulating therapy entails a general higher risk for both bacterial and viral infections. This interrelation could be relevant in the current outbreak of COVID-19 where infected patients undergoing immune modulating therapy are thought to have increased risk for severe and complicated disease course. “Danish Society of Gastroenterology and Hepatology” has recommended to maintain the immune modulating therapy during the epidemy but endorse extra caution and awareness of preventing transmission.   By Johan Burisch, MD, PhD, Gastrounit, Medical division, Copenhagen University Hospital Hvidovre  Klaus Theede, chief physician, MD, PhD, Gastrounit, Medical division, Copenhagen ...

According to The European Crohn’s and Colitis Organization (ECCO), patients under immunosuppressive/immunomodulatory treatment are not in a significant increased risk of catching COVID-19. As the risk of severe infections is slightly higher in patients under immunosuppression therapies, it is expected that the same might occur in SARS-CoV-2 infections. But data from immunosuppressed patients and SARS-CoV-2 ...